For example, an increased ratio of CD8+/CD4+ CD3+ T cells and a number of IFN-γ+CD8+ CD3+ T cells can be used to predict enhanced tumour-specific T cell responses in the combination therapy of galunisertib and intestinal microbiota in HCC [173]. This evidence concerns the gene CD4 and neoplasm.